Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Biochim Pol ; 70(4): 911-917, 2023 Dec 07.
Article in English | MEDLINE | ID: mdl-38060820

ABSTRACT

BACKGROUND: We aimed to analyze the value of serum (sdLDLc*HCYc)/HDLc ratio in the stability of intracranial arterial plaques among patients with acute cerebral infarction. METHODS: A retrospective analysis was conducted on 140 patients with acute cerebral infarction admitted to the neurology department and 101 healthy individuals for regular examinations in our hospital from 2013 to 2019, who were respectively allocated into the study group and the control group. Participants in both groups were measured for serum sdLDLc, HDLc, and HCYc using peroxidase method, enzyme-linked immunosorbent assay, and enzyme method, respectively. The laboratory indexes of the two groups were compared. The multivariate logistic regression analysis was done to analyze the influencing factors of the stability of intracranial artery plaque in patients with acute cerebral infarction. The value of high-density lipoprotein cholesterol (HDL-C), homocysteine, sdLDLc, (sdLDLc*HCYc)/HDLc in diagnosing the stability of intracranial artery plaque was also evaluated in patients with acute cerebral infarction. RESULTS: There was no distinct difference in height, hypertension, diabetes, coronary heart disease, smoking history and drinking history between the two groups (P>0.05). The study group showed statistically significant differences in age, gender, weight, and BMI (P<0.05). The current study demonstrated no statistical difference in the levels of TG, low-density lipoprotein cholesterol (LDL-C), α-lipoprotein, and HCYc between the two groups (P>0.05). However, the levels of TC, HDL-C, sdLDLc, (sdLDLc*HCYc)/HDLc in the study group were significantly different when comparing with the control group (P<0.05). No statistically significant difference was found in the levels of TG, triglycerides, LDL-C, α-lipoprotein, and HCYc among patients with different degrees of stenosis in the study group (P>0.05). The level of HDL-C was significantly lower in cases of severe stenosis compared to no stenosis, mild stenosis and moderate stenosis, with severe stenosis showing the lowest levels; mild stenosis had lower levels than no stenosis, while moderate stenosis had lower levels than both no stenosis and mild stenosis (P<0.05). The levels of sdLDLc, (sdLDLc*HCYc)/HDLc exhibited a significant increase in cases of severe stenosis as compared tono stenosis, mild stenosis, and moderate stenosis. Furthermore, the levels of sdLDLc, (sdLDLc*HCYc)/HDLc were found to be higher in moderate stenosis as compared to no stenosis and mild stenosis. Similarly, the levels of sdLDLc, (sdLDLc*HCYc)/HDLc were observed to be higher in mild stenosis than no stenosis (P<0.05).The independent variables were set as the indicators with difference in single factor comparison, including age, gender, BMI, TC, LDL-C, HDL-C, HCYc, sdLDLc, (sdLDLc*HCYc)/HDLc. The dependent variable was the stability of intracranial artery plaque in patients with acute cerebral infarction. After variable selection, the results showed that the factors influencing the stability of intracranial artery plaque in patients with acute cerebral infarction were age, BMI, (sdLDLc*HCYc)/HDLc. The degree of plaque enhancement was used as a criterion to reflect the stability of plaque. ROC curve analysis showed that (sdLDLc*HCYc)/HDLc had a higher evaluation value for the stability of intracranial artery plaque than HDL-C, homocysteine, and sdLDLc in patients with acute cerebral infarction. CONCLUSION: The serum (sdLDLc*HCYc)/HDLc ratio was found to have potential in evaluating the stability of intracranial arterial plaques in patients with acute cerebral infarction.


Subject(s)
Brain Ischemia , Plaque, Atherosclerotic , Humans , Retrospective Studies , Cholesterol, LDL , Constriction, Pathologic , Arteries , Cholesterol, HDL , Acute Disease , Cerebral Infarction/complications , Homocysteine
2.
BMC Neurol ; 20(1): 414, 2020 Nov 13.
Article in English | MEDLINE | ID: mdl-33183255

ABSTRACT

BACKGROUND: Acute ischemic stroke (AIS) is one of the leading causes of mortality and long-term disability worldwide. Our study aims to clarify the role of low-density lipoproteins (LDL) subclasses in the occurrence of AIS and develop a risk xprediction model based on these characteristics to identify high-risk people. METHODS: Five hundred and sixty-six patients with AIS and 197 non-AIS controls were included in this study. Serum lipids and other baseline characteristics including fasting blood glucose (GLU), serum creatinine (Scr), and blood pressure were investigated in relation to occurrence of AIS. The LDL subfractions were classified and measured with the Lipoprint System by a polyacrylamide gel electrophoresis technique. RESULTS: Levels of LDL-3, LDL-4 and LDL-5 subclasses were significantly higher in the AIS group compared to the non-AIS group and lower level of LDL-1 was prevalent in the AIS patients. Consistently, Spearman correlation coefficient demonstrated that sd-demonevels, especially LDL-3 and LDL-4 levels, were significantly positively correlated with AIS. Furthermore, there is a significant positive correlation between small dense LDL (sd-LDL, that is LDL-3 to 7) levels and serum lipids including total cholesterol (TC), Low density lipoprotein cholesterol (LDL-C), and Triglyceride (TG). Increased LDL-3 and LDL-4 as well as decreased LDL-1 and LDL-2 were correlated to the occurrence of AIS, even in the people with normal LDL-C levels. A new prediction model including 12 variables can accurately predict the AIS risk in Chinese patients (AUC = 0.82 ± 0.04). CONCLUSIONS: Levels of LDL subclasses should be considered in addition to serum LDL-C in assessment and management of AIS. A new prediction model based on clinical variables including LDL subtractions can help clinicians identify high of AIS, even in the people with norm.


Subject(s)
Cholesterol, LDL , Ischemic Stroke , Case-Control Studies , China/epidemiology , Cholesterol, LDL/blood , Cholesterol, LDL/classification , Humans , Ischemic Stroke/blood , Ischemic Stroke/epidemiology , Risk Factors
3.
J Mol Neurosci ; 64(3): 363-373, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29417448

ABSTRACT

Inflammatory damage aggravates the progression of Alzheimer's disease (AD) and the mechanism of inflammatory damage may provide a new therapeutic window for the treatment of AD. Toll-like receptor 4 (TLR4)-mediated signaling can regulate the inflammatory process. However, changes in TLR4 signaling pathway induced by beta-amyloid (Aß) have not been well characterized in brain, especially in the hippocampus. In the present study, we explored the changes of TLR4 signaling pathway induced by Aß in the hippocampus and the role of atorvastatin in modulating this signal pathway and neurotoxicity induced by Aß. Experimental AD rats were induced by intrahippocampal injection of Aß1-42, and the rats were treated with atorvastatin by oral gavage from 3 weeks before to 6 days after injections of Aß1-42. To determine the spatial learning and memory ability of rats in the AD models, Morris water maze (MWM) was performed. The expression of the glial fibrillary acidic protein (GFAP), ionized calcium binding adapter molecule-1 (Iba-1), TLR4, tumor necrosis factor receptor-associated factor 6 (TRAF6), and nuclear transcription factor (NF)-κB (NF-κB) protein in the hippocampus was detected by immunohistochemistry and Western blot. Compared to the control group, increased expression of TLR4, TRAF6, and NF-κB was observed in the hippocampus at 7 days post-injection of Aß (P < 0.01). Furthermore, atorvastatin treatment significantly ameliorated cognitive deficits of rats, attenuated microglia and astrocyte activation, inhibited apoptosis, and down-regulated the expression of TLR4, TRAF6, and NF-κB, both at the mRNA and protein levels (P < 0.01). TLR4 signaling pathway is thus actively involved in Aß-induced neuroinflammation and atorvastatin treatment can exert the therapeutic benefits for AD via the TLR4 signaling pathway.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Atorvastatin/therapeutic use , Cognitive Dysfunction/drug therapy , NF-kappa B/metabolism , Neuroprotective Agents/therapeutic use , TNF Receptor-Associated Factor 6/metabolism , Toll-Like Receptor 4/metabolism , Amyloid beta-Peptides/toxicity , Animals , Cognitive Dysfunction/etiology , Male , Peptide Fragments/toxicity , Rats , Rats, Sprague-Dawley
4.
Neurol Res ; 39(7): 632-639, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28330425

ABSTRACT

OBJECTIVE: Discussed the protection of taxane-derived compounds, 7-deacetyl-taxine B and 5-cinnamoyloxy-taxin B, against oxidative stress injury. METHODS: SK-N-SH cells were pretreated with 7-deacetyl-taxine B, 5-cinnamoyloxy-taxin B or DMSO (control) and then incubated with H2O2 for another 24 h. Cell viability was measured by MTT colorimetric assay. Apoptosis rate, reactive oxygen species (ROS) and mitochondrial membrane potential (MMP) were detected using flow cytometry assay. Ultrastructure was detected by Transmission electron microscope. RESULTS: Taxane-derived compounds improved H2O2 mediated loss of cell viability in SK-N-SH cell. Ultrastructure of control group cells showed nucleus shrinkage, dense aggregation of chromatin, appearance of apoptotic body and mitochondrial dilation. Treated group showed alleviation of mitochondrial dilation and chromatin margination, and reduction of apoptosis cells induced by H2O2. The apoptosis rate was decreased in treated group compared with control group. DCFH-DA staining showed that ROS were significantly decreased in cells treated with taxane-derived compounds compared with control group. Rhodamine123 staining showed that MMP was significantly decreased in cells treated with taxane-derived compounds compared with control group. CONCLUSION: The anti-oxidative stress and neuroprotective effect of taxane-derived compounds was verified here, wherein it could protect neurocytes from H2O2-induced oxidative stress injury.


Subject(s)
Antioxidants/pharmacology , Hydrogen Peroxide/toxicity , Neuroprotective Agents/pharmacology , Oxidative Stress/drug effects , Taxoids/pharmacology , Apoptosis/drug effects , Apoptosis/physiology , Cell Line, Tumor , Cell Nucleus/drug effects , Cell Nucleus/metabolism , Cell Nucleus/ultrastructure , Cell Survival/drug effects , Cell Survival/physiology , Dimethyl Sulfoxide/pharmacology , Humans , Membrane Potential, Mitochondrial/drug effects , Mitochondria/drug effects , Mitochondria/metabolism , Mitochondria/ultrastructure , Oxidative Stress/physiology , Reactive Oxygen Species/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...